Evidence map›Paper›PMID 39673668›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2024

Excess shed mesothelin disrupts pancreatic cancer cell clustering to impair peritoneal colonization.

Theressa Ewa, Neel Panchwagh, Chin-Hsien Tai, Leela Rani Avula, Sarah Joseph, Michael W Rudloff, Nargis Malik, Xianyu Zhang, Christine Alewine

Abstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Excess shed mesothelin disrupts pancreatic cancer cell clustering to impair peritoneal colonization.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Theressa EwaLaboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID https://orcid.org/0009-0008-6169-1577
Neel PanchwaghLaboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0003-0999-2870
Chin-Hsien TaiLaboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0003-4766-0535
Leela Rani AvulaLaboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0001-9920-9506
Sarah JosephLaboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID https://orcid.org/0009-0001-1279-8166
Michael W RudloffLaboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0002-2950-1218
Nargis MalikLaboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0003-1294-1660
Xianyu ZhangLaboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID https://orcid.org/0009-0001-6336-5010
Christine AlewineLaboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0003-1661-0957

Funding

Precision Therapy to Target Pancreatic Ductal AdenocarcinomaZIABC011652 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ALEWINE, CHRISTINE · 2015 to 2025
$7.9M
HHS | NIH | National Cancer Institute (NCI) ZIA BC 011652Intramural NIH HHS ZIA BC011652
6 · The paper itself

Abstract

Peritoneum is the second most common site of metastasis in patients with pancreatic ductal adenocarcinoma (PDAC). Peritoneal colonization is impaired in PDAC cells with knockout (KO) of the cancer surface antigen mesothelin (MSLN) or by introducing Y318A mutation in MSLN to prevent binding to mucin-16 (MUC-16). MSLN has a membrane-bound form but is also shed to release soluble MSLN (sMSLN). Their individual roles in peritoneal metastasis are unknown. Here, a C-terminal truncated MSLN mutant (∆591) incapable of cell membrane insertion but proficient in secretion was engineered. Expression of ∆591 MSLN failed to rescue peritoneal metastasis in MSLN KO cells and inhibited peritoneal colonization when overexpressed in WT PDAC cells. Exposing PDAC cells to conditioned medium (CM) containing excess sMSLN impaired cancer cell clustering in vitro and in peritoneal fluid in vivo, while CM containing only Y318A sMSLN did not. These data demonstrate that interaction of membrane-bound MSLN with MUC-16 promotes cell clustering that is critical for efficient peritoneal metastasis. However, peritoneal colonization by MSLN KO cells was rescued by expression of ∆591 mutant MSLN bearing Y318A mutation, suggesting that sMSLN also has a MUC-16-independent role in peritoneal spread. Alterations in inflammatory signaling pathways occurred following KO cell exposure to CM containing sMSLN, and CM from cancer cells with intact peritoneal metastasis provoked increased KO cell secretion of IL-1α. While excess sMSLN inhibits cell clustering and peritoneal colonization, sMSLN may also promote PDAC peritoneal metastasis independent of MUC-16.

Indexed as

GPI-Linked ProteinsMesothelinPancreatic NeoplasmsPeritoneal NeoplasmsAnimalsCA-125 AntigenCarcinoma, Pancreatic DuctalCell Line, TumorHumansMembrane ProteinsMiceCA-125 AntigenGPI-Linked ProteinsMembrane ProteinsMesothelinMSLN protein, humanMsln protein, mouseMUC16 protein, humancell clusteringIL‐1αmesothelinpancreatic cancerperitoneal metastasis

Identifiers

PMID39673668
PMCPMC11646052

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.